年末关注红利资产 建信基金多只红利产品各具特色
Zhong Guo Jing Ji Wang·2025-12-30 03:24

Group 1 - The article highlights a renewed focus on dividend assets as investors seek stability amid market fluctuations, with significant inflows into dividend-themed ETFs recently [1] - The technology sector, represented by AI, has seen strong growth until the third quarter of 2025, while the dividend sector experienced a correction; however, since October, funds have been returning to the dividend sector due to market divergence and overseas liquidity impacts [1] - The current low interest rate environment and year-end market volatility position the dividend sector as a "ballast" for investors looking to balance risk in their portfolios [1] Group 2 - As of December 26, the dividend yield of the CSI Dividend Index reached 5.14%, compared to a 10-year government bond yield of 1.84%, indicating a favorable environment for dividend investments [1] - Recent policies, including the "New Nine Articles," have encouraged listed companies to optimize their dividend policies, leading to increased cash dividend enthusiasm among A-share companies [1] - Long-term funds, such as social security funds and insurance capital, are expected to increase their allocation to the dividend sector, especially as some institutional funds may shift from growth stocks to dividend stocks to secure annual returns [1] Group 3 - The article provides insights into various dividend-themed products offered by Jianxin Fund, including the CSI 300 Dividend Index and the CSI Dividend Potential Index, which focus on high dividend yield and strong dividend capability companies [2] - As of September 30, Jianxin's ETFs have significantly outperformed their benchmarks, with returns of 30.92% and 30.20% over three years, compared to benchmarks of 17.31% and 16.63% [2] - Jianxin's high dividend theme fund has a diversified portfolio, with 30.38% of its holdings in Hong Kong stocks, focusing on traditional high-dividend sectors like utilities, while also including sectors like telecommunications and pharmaceuticals [2]